Literature DB >> 33407381

Predicting Gleason sum upgrading from biopsy to radical prostatectomy pathology: a new nomogram and its internal validation.

Xiaochuan Wang1, Yu Zhang1, Fengbo Zhang1, Zhengguo Ji1, Peiqian Yang1, Ye Tian2.   

Abstract

BACKGROUND: To explore the rate of Gleason sum upgrading (GSU) from biopsy to radical prostatectomy pathology and to develop a nomogram for predicting the probability of GSU in a Chinese cohort.
METHODS: We retrospectively reviewed our prospectively maintained prostate cancer (PCa) database from October 2012 to April 2020. 198 patients who met the criteria were enrolled. Multivariable logistic regression analysis was performed to determine the predictors. Nomogram was constructed based on independent predictors. The receiver operating curve was undertaken to estimate the discrimination. Calibration curve was used to assess the concordance between predictive probabilities and true risks.
RESULTS: The rate of GSU was 41.4%, whilst GS concordance rate was 44.4%. The independent predictors are prostate specific antigen (PSA), greatest percentage of cancer (GPC), clinical T-stage and Prostate Imaging Reporting and Data System (PI-RADS) score. Our model showed good discrimination (AUC of 0.735). Our model was validated internally with good calibration with bias-corrected C-index of 0.726.
CONCLUSIONS: Utilization of basic clinical variables (PSA and T-stage) combined with imaging variable (PI-RADS) and pathological variable (GPC) could improve performance in predicting actual probabilities of GSU in the 24-core biopsy scheme. Our nomogram could help to assess the true risk and make optimal treatment decisions for PCa patients.

Entities:  

Keywords:  Biopsy; Neoplasm grading; Nomograms; Prostatectomy; Prostatic neoplasms; needle

Mesh:

Year:  2021        PMID: 33407381      PMCID: PMC7789761          DOI: 10.1186/s12894-020-00773-5

Source DB:  PubMed          Journal:  BMC Urol        ISSN: 1471-2490            Impact factor:   2.264


  27 in total

1.  Multiparametric 3T MRI for the prediction of pathological downgrading after radical prostatectomy in patients with biopsy-proven Gleason score 3 + 4 prostate cancer.

Authors:  Tatsuo Gondo; Hedvig Hricak; Evis Sala; Junting Zheng; Chaya S Moskowitz; Melanie Bernstein; James A Eastham; Hebert Alberto Vargas
Journal:  Eur Radiol       Date:  2014-08-07       Impact factor: 5.315

Review 2.  Active surveillance for clinically localized prostate cancer--a systematic review.

Authors:  Frederik B Thomsen; Klaus Brasso; Laurence H Klotz; M Andreas Røder; Kasper D Berg; Peter Iversen
Journal:  J Surg Oncol       Date:  2014-03-07       Impact factor: 3.454

3.  The novel nomogram of Gleason sum upgrade: possible application for the eligible criteria of low dose rate brachytherapy.

Authors:  Lars Budäus; Markus Graefen; Georg Salomon; Hendrik Isbarn; Giovanni Lughezzani; Maxine Sun; Felix K H Chun; Thorsten Schlomm; Thomas Steuber; Alexander Haese; Jens Koellermann; Guido Sauter; Margit Fisch; Hans Heinzer; Hartwig Huland; Pierre I Karakiewicz
Journal:  Int J Urol       Date:  2010-08-31       Impact factor: 3.369

4.  Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades.

Authors:  Jonathan I Epstein; Zhaoyong Feng; Bruce J Trock; Phillip M Pierorazio
Journal:  Eur Urol       Date:  2012-02-08       Impact factor: 20.096

5.  Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.

Authors:  Anthony V D'Amico; Ming-Hui Chen; Andrew A Renshaw; Marian Loffredo; Philip W Kantoff
Journal:  JAMA       Date:  2008-01-23       Impact factor: 56.272

6.  Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and Recommendations for Use.

Authors:  Jelle O Barentsz; Jeffrey C Weinreb; Sadhna Verma; Harriet C Thoeny; Clare M Tempany; Faina Shtern; Anwar R Padhani; Daniel Margolis; Katarzyna J Macura; Masoom A Haider; Francois Cornud; Peter L Choyke
Journal:  Eur Urol       Date:  2015-09-08       Impact factor: 20.096

7.  A nomogram for predicting upgrading in patients with low- and intermediate-grade prostate cancer in the era of extended prostate sampling.

Authors:  Ayman S Moussa; Michael W Kattan; Ryan Berglund; Changhong Yu; Khaled Fareed; J Stephen Jones
Journal:  BJU Int       Date:  2009-08-13       Impact factor: 5.588

8.  Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.

Authors:  Umberto Capitanio; Pierre I Karakiewicz; Luc Valiquette; Paul Perrotte; Claudio Jeldres; Alberto Briganti; Andrea Gallina; Nazareno Suardi; Andrea Cestari; Giorgio Guazzoni; Andrea Salonia; Francesco Montorsi
Journal:  Urology       Date:  2009-02-04       Impact factor: 2.649

9.  The Impact of Prostate Cancer Upgrading and Upstaging on Biochemical Recurrence and Cancer-Specific Survival.

Authors:  Arnas Bakavičius; Mingailė Drevinskaitė; Kristina Daniūnaitė; Marija Barisienė; Sonata Jarmalaitė; Feliksas Jankevičius
Journal:  Medicina (Kaunas)       Date:  2020-02-04       Impact factor: 2.430

10.  Nomograms for predicting Gleason upgrading in a contemporary Chinese cohort receiving radical prostatectomy after extended prostate biopsy: development and internal validation.

Authors:  Biming He; Rui Chen; Xu Gao; Shancheng Ren; Bo Yang; Jianguo Hou; Linhui Wang; Qing Yang; Tie Zhou; Lin Zhao; Chuanliang Xu; Yinghao Sun
Journal:  Oncotarget       Date:  2016-03-29
View more
  1 in total

1.  Prostate Health Index (phi) and its derivatives predict Gleason score upgrading after radical prostatectomy among patients with low-risk prostate cancer.

Authors:  Jia-Qi Yan; Da Huang; Jing-Yi Huang; Xiao-Hao Ruan; Xiao-Ling Lin; Zu-Jun Fang; Yi Gao; Hao-Wen Jiang; Yi-Shuo Wu; Rong Na; Dan-Feng Xu
Journal:  Asian J Androl       Date:  2022 Jul-Aug       Impact factor: 3.054

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.